BiotechTube

LUM001 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alagille Syndrome

Conditions

Alagille Syndrome

Trial Timeline

Aug 1, 2013 → Mar 1, 2015

NCT ID
NCT01903460

About LUM001 + Placebo

LUM001 + Placebo is a phase 2 stage product being developed by Mirum Pharmaceuticals for Alagille Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01903460. Target conditions include Alagille Syndrome.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT02057692Phase 2Completed
NCT01903460Phase 2Completed

Competing Products

9 competing products in Alagille Syndrome

See all competitors
ProductCompanyStageHype Score
Odevixibat + PlaceboIpsenPhase 3
74
OdevixibatIpsenPhase 3
74
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
maralixibatMirum PharmaceuticalsPre-clinical
20
Livmarli + LivmarliMirum PharmaceuticalsPre-clinical
20
LUM001 (Maralixibat)Mirum PharmaceuticalsPhase 2
49
LUM001 (Maralixibat) + PlaceboMirum PharmaceuticalsPhase 2
49
Livmarli Oral ProductMirum PharmaceuticalsApproved
82
LUM001 + PlaceboMirum PharmaceuticalsPhase 2
49

Other Products from Mirum Pharmaceuticals

Livmarli Oral ProductApproved
82
MaralixibatPhase 3
74
Cholic AcidsPhase 3
74
MaralixibatPhase 3
74
Cholic acidPhase 3
74